Clinical Trial Update: Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024) [Phase 3]

View source ↗

Summary

Phase 3 trial MK-8591-024 evaluating once-monthly oral islatravir for HIV PrEP in at-risk men and transgender women has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Islatravir (Islatravir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV Preexposure Prophylaxis | Phase 3 | Status: TERMINATED | Results posted: 2024-12-11